Streetbeat News

Stock Prices

LAZ

Analysts have varied opinions on Lazard (NYSE:LAZ), with recent ratings showing a mix of somewhat bullish and bearish sentiments. The average 12-month price target has increased to $51.8. Lazard's financials reveal strong ROE and ROA but challenges with net margin and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 3:00 pm

ZBIO

Zenas BioPharma, Inc (NASDAQ:ZBIO) is set to IPO on September 13 on the NASDAQ, offering shares priced between $16.00 and $18.00. The company focuses on immunology-based therapies and has a 180-day insider lock-up period ending March 12, 2025.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 3:00 pm

DBD

Diebold Nixdorf (NYSE:DBD) has been analyzed by four analysts, with ratings ranging from bullish to somewhat bullish. The average 12-month price target has increased to $53.75. The company shows positive revenue growth but faces challenges with high debt and low ROE.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 3:00 pm

MBX

MBX Biosciences, Inc is set to start trading on the NASDAQ under the ticker MBX on September 13. The IPO price is expected to be between $14.00 and $16.00 per share, with a 180-day insider lock-up period.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 3:00 pm

BCAX

Bicara Therapeutics Inc is set to IPO on September 13, 2023, on the NASDAQ under the ticker BCAX, with shares priced between $16.00 and $18.00. The company focuses on bifunctional therapies for solid tumors.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 3:00 pm

JBDI

JBDI Holdings experienced a significant drop in its stock price, triggering a circuit breaker halt as the stock fell by 27.8%.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 2:58 pm

GV

Visionary Holdings Inc. (NASDAQ:GV) has signed a Memorandum of Understanding with Saudi Arabia's Public Investment Fund (PIF) for a $120 million investment. This partnership aims to support Visionary's projects in AI, education, and real estate, and is expected to boost the company's market value and industrial expansion.

Portfolio Pulse from Lekha Gupta

September 12, 2024 | 2:58 pm

ONCT

Oncternal Therapeutics shares fell after the company announced the discontinuation of its clinical trials for ONCT-535 and ONCT-808 due to insufficient results and high costs.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 2:55 pm

RYDE

Ryde Group shares have been halted due to a circuit breaker after experiencing a significant drop of 78.6%.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 2:55 pm